Literature DB >> 17613711

Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction.

Adarsh M Kumar1, Irina Borodowsky, Benny Fernandez, Louis Gonzalez, Mahendra Kumar.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) enters the central nervous system shortly after the infection and becomes localized in different regions of the brain, leading to various neurological abnormalities including motor disorders and neurocognitive deficits. Although HIV-1-associated functional abnormalities of the central nervous system (CNS) can be evaluated during life by using various test batteries, HIV-1 virus concentration in different brain regions can be measured only after death. The tissues obtained at autopsy provide a valuable source for determining the role of various factors, including that of HIV-1 viral load in the CNS, that may contribute to the regional CNS neuropathogenesis. For this study, we obtained from the National Institutes of Health-sponsored National NeuroAIDS Tissue Consortium (NNTC) the tissues from different brain regions collected at autopsy of HIV-1-positive (N = 38) and HIV-negative (N = 11) individuals, with postmortem intervals of 2 to 29 h, and measured HIV-1 RNA concentration in the frontal cortex, frontal cortex area 4, frontal cortex area 6, basal ganglia, caudate nucleus, putamen, globus pallidus, substantia nigra, and cerebrospinal fluid. Because HIV-1+ individuals were infected with the virus for up to 21 years and the majority of them had used highly active antiretroviral therapy (HAART), we used highly sensitive real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay in order to detect a wide dynamic range of HIV-1 RNA with lower detection limit of a single copy. The primers and probes were from the long terminal repeat (LTR) region of HIV genome for achieving higher specificity and sensitivity of detection and amplification. Our results demonstrate a wide variation in the concentration of HIV-1 RNA in different brain regions (5.51 and 8,144,073; log(10) 0.74 and 6.91 copies/g tissue), and despite the high specificity and sensitivity of this method, viral RNA was not detected in 50% of all the samples, and in 30% to 64% of samples of each region of HIV-1+ individuals. However, the highest concentration of viral RNA was found in the caudate nucleus and the lowest concentration in the frontal cortex and cerebrospinal fluid. The viral RNA was undetectable in all samples of HIV-negative individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613711     DOI: 10.1080/13550280701327038

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  71 in total

1.  Distribution of brain HIV load in AIDS.

Authors:  C A Wiley; V Soontornniyomkij; L Radhakrishnan; E Masliah; J Mellors; S A Hermann; P Dailey; C L Achim
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

2.  Treating AIDS dementia.

Authors:  S A Lipton
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

3.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.

Authors:  G Pialoux; S Fournier; A Moulignier; J D Poveda; F Clavel; B Dupont
Journal:  AIDS       Date:  1997-08       Impact factor: 4.177

Review 4.  Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome.

Authors:  S A Lipton; H E Gendelman
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

5.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

6.  Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry.

Authors:  O Bagasra; E Lavi; L Bobroski; K Khalili; J P Pestaner; R Tawadros; R J Pomerantz
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

Review 7.  Chemokine receptors and virus entry in the central nervous system.

Authors:  D Gabuzda; J Wang
Journal:  J Neurovirol       Date:  1999-12       Impact factor: 2.643

8.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Brain viral burden in HIV infection.

Authors:  C L Achim; R Wang; D K Miners; C A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  1994-05       Impact factor: 3.685

10.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.

Authors:  P M Holland; R D Abramson; R Watson; D H Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more
  73 in total

1.  Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Ceereena Ubaida-Mohien; Julia L Drewes; Zhaohao Liao; Lucio Gama; Kenneth W Witwer; David R Graham; M Christine Zink
Journal:  J Infect Dis       Date:  2014-03-31       Impact factor: 5.226

Review 2.  Neuropharmacologic Approaches to Restore the Brain's Microenvironment.

Authors:  Weizhe Li; Hsin-I Tong; Santhi Gorantla; Larisa Y Poluektova; Howard E Gendelman; Yuanan Lu
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

3.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

4.  Discordance between peripheral and colonic markers of inflammation during suppressive ART.

Authors:  Richard M Dunham; Ivan Vujkovic-Cvijin; Steven A Yukl; Mara J Broadhurst; Pʼng Loke; Rebecca G Albright; Joseph K Wong; Michael M Lederman; Ma Somsouk; Peter W Hunt; Jeffrey N Martin; Steven G Deeks; Joseph M McCune
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

5.  SIV/macaque model of HIV infection in cocaine users: minimal effects of cocaine on behavior, virus replication, and CNS inflammation.

Authors:  Michael Weed; Robert J Adams; Robert D Hienz; Kelly A Meulendyke; Michael E Linde; Janice E Clements; Joseph L Mankowski; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-28       Impact factor: 4.147

Review 6.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

7.  National Institute on Drug Abuse symposium report: drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; Jerry Frankenheim; Albert Avila; Roger Sorensen; Joni Rutter
Journal:  J Neurovirol       Date:  2013-03-01       Impact factor: 2.643

8.  BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.

Authors:  Yanhui Cai; Mohamed Abdel-Mohsen; Costin Tomescu; Fengtian Xue; Guoxin Wu; Bonnie J Howell; Yong Ai; Jie Sun; Livio Azzoni; Carole Le Coz; Neil Romberg; Luis J Montaner
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

9.  Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.

Authors:  Charlene Wang; Mohamed Abdel-Mohsen; Matthew C Strain; Steven M Lada; Steven Yukl; Leslie R Cockerham; Christopher D Pilcher; Frederick M Hecht; Elizabeth Sinclair; Teri Liegler; Douglas D Richman; Steven G Deeks; Satish K Pillai
Journal:  J Infect Dis       Date:  2014-06-16       Impact factor: 5.226

10.  Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

Authors:  Guochun Jiang; Erica A Mendes; Philipp Kaiser; Sumathi Sankaran-Walters; Yuyang Tang; Mariana G Weber; Greg P Melcher; George R Thompson; Amilcar Tanuri; Luiz F Pianowski; Joseph K Wong; Satya Dandekar
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.